New Zealand markets closed

Qiagen N.V. (QGEN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
46.15+0.32 (+0.70%)
At close: 04:00PM EDT
46.15 +0.02 (+0.03%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close45.83
Bid35.04 x 800
Ask53.00 x 900
Day's range45.58 - 46.15
52-week range40.38 - 51.18
Avg. volume658,347
Market cap10.509B
Beta (5Y monthly)0.39
PE ratio (TTM)25.08
EPS (TTM)1.84
Earnings date24 Apr 2023 - 28 Apr 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est54.04
  • Business Wire

    QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results

    VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.

  • Zacks

    QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact

    QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.

  • Business Wire

    QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug

    VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).